Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
April 14, 2020
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Balázs Bálint, Márton Csékei, Zoltán Szabó, Zoltán Szlávik, András Kotschy, Maïa Chanrion, Olivier Geneste, I-Jen Chen, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Levente Ondi, Ágnes Proszenyák
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Application
Filed:
June 28, 2019
Publication date:
January 2, 2020
Applicants:
Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
Type:
Grant
Filed:
February 14, 2018
Date of Patent:
November 26, 2019
Assignees:
GALAPAGOS NV, LES LABORATOIRES SERVIER
Inventors:
Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
Abstract: Compounds of formula (I): wherein R1, R2, R5, R6, R7, R12, X, Y, A, E and n are as defined in the description. Medicinal products containing the same which are useful in treating a condition requiring a pro-apoptotic agent.
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
October 29, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Zoltán Szlávik, Zoltán Szabó, Márton Csékei, Attila Paczal, András Kotschy, Alain Bruno, Olivier Geneste, I-Jen Chen, James Edward Paul Davidson, James Brooke Murray, Levente Ondi, Gábor Radics, Szabolcs Sipos, Ágnes Proszenyák, Françoise Perron-Sierra, Balázs Bálint
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6 and Y are as defined in the description. Medicaments.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
October 29, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Attila Paczal, Zoltán Szlávik, András Kotschy, Maïa Chanrion, Ana Leticia Maragno, Olivier Geneste, Didier Demarles, Balázs Bálint, Szabolcs Sipos
Abstract: Compounds of formula (I) wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
Type:
Grant
Filed:
February 27, 2018
Date of Patent:
September 17, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Arnaud Le Tiran, Thierry Le Diguarher, Jérôme-Benoît Starck, Jean-Michel Henlin, Guillaume De Nanteuil, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
August 20, 2019
Assignees:
Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
August 20, 2019
Assignees:
Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
August 20, 2019
Assignees:
Les Laboratoires Servier, Institut National de la Santè, Centre National de la Recherche Scientifique (CNRS)
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
March 6, 2017
Date of Patent:
August 13, 2019
Assignees:
Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: The present disclosure provides methods and compositions useful for preventing gastrointestinal and/or colorectal cancer in animals, including humans, having pre-cancerous adenomatous polyps. The present disclosure provides compositions comprising anti-PG antibodies suitable for use in the methods of the disclosure. The present disclosure also provides methods and compositions useful for monitoring the efficacy of anti-PG treatment in subjects with pre-cancerous polyps.
Type:
Grant
Filed:
September 28, 2016
Date of Patent:
August 6, 2019
Assignees:
Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, A and n are as defined in the description.
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
June 18, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Zoltan Szlavik, Attila Paczal, Balazs Balint, András Kotschy, Maïa Chanrion, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Ágnes Proszenyák
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, W, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
June 18, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
Balazs Balint, Márton Csékei, Zoltán Szabó, Zoltan Szlavik, András Kotschy, Maïa Chanrion, Olivier Geneste, I-Jen Chen, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Levente Ondi, Ágnes Proszenyák
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
Type:
Grant
Filed:
April 20, 2017
Date of Patent:
May 7, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
Inventors:
András Kotschy, Zoltán Szlávik, Márton Csékei, Attila Paczal, Zoltán Szabó, Szabolcs Sipos, Gábor Radics, Ágnes Proszenyák, Balázs Bálint, Alain Bruno, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Françoise Perron-Sierra
Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
Type:
Grant
Filed:
January 30, 2017
Date of Patent:
April 23, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALS (R&D) LTD
Inventors:
Arnaud Le Tiran, Thierry Le Diguarher, Jérôme-Benoît Starck, Jean-Michel Henlin, Anne-Françoise Guillouzic, Guillaume De Nanteuil, Olivier Geneste, Imre Fejes, János Tatai, Miklós Nyerges, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Didier Durand
Abstract: 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione methanesulphonate of formula (II): Medicinal products containing the same which are useful in treating cancer.
Type:
Grant
Filed:
September 4, 2018
Date of Patent:
April 2, 2019
Assignee:
LES LABORATOIRES SERVIER
Inventors:
Alexandre Le Flohic, Jérôme Guidotti, Philippe Letellier
Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R13, Ra, Rb, A and n are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.
Type:
Grant
Filed:
June 22, 2016
Date of Patent:
March 12, 2019
Assignees:
LES LABORATOIRES SERVIER, VERNALIS &R&D) LTD.
Inventors:
Zoltan Szlavik, András Kotschy, Maïa Chanrion, Didier Demarles, Olivier Geneste, James Edward Paul Davidson, James Brooke Murray, Szabolcs Sipos, Attila Paczal, Balazs Balint
Abstract: Compounds of formula (I) wherein: Ak1 represents an alkyl chain, X represents —(CH2)m—, —CH(R)—, —N(R)—, —CH2—N(R)—, —N(R)—CH2— or —CH2—N(R)—CH2—, m and R are as defined in the description, R1 and R2 each represent H when X represents —(CH2)m—, —CH(R)—, —N(R)—, —CH2—N(R)— or —N(R)—CH2—, or together form a bond when X represents —CH2—N(R)—CH2—, R3 represents NH2, Cy-NH2, Cy-Ak3-NH2 or piperidin-4-yl, Cy and Ak3 are as defined in the description, R4 and R5, which may be identical or different, each represent H or F, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating conditions requiring a TAFIa inhibitor.
Type:
Grant
Filed:
January 13, 2017
Date of Patent:
November 27, 2018
Assignee:
LES LABORATOIRES SERVIER
Inventors:
Philippe Gloanec, Arnaud-Pierre Schaffner, Patricia Sansilvestri-Morel, Alain Rupin, Philippe Mennecier, Marie-Odile Vallez
Abstract: Composition for the prolonged release of trimetazidine wherein the inner phase comprises trimetazidine and the outer layer comprises a retardant and an anti-agglomerant.
Type:
Grant
Filed:
January 29, 2013
Date of Patent:
November 6, 2018
Assignee:
LES LABORATOIRES SERVIER
Inventors:
Patrick Genty, Christophe Hermelin, Jean-Manuel Pean